The only mutation in the EGFR ECD was Y112C, which was detected in the PD1 sample of a patient with an RAS wild type tumor, who received first-line anti-EGFR therapy (S29 in Figure 3 and Supplementary Table S2). This evidence concerns the gene EGFR and neoplasm.